TRANSDERMAL SKIN PATCHES MARKET ANALYSIS

Transdermal Skin Patches Market, By Type (Single-layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive, Matrix, and Others), By Application (Pain Relief, Smoking Cessation, Overactive Bladder, Hormonal Therapy, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

On January 2, 2024, Starton Therapeutics, a biotechnology company, announced that they had launched STARSILON a novel proprietary transdermal patch delivery platform. Novel platform technology potentially expands the number of active pharmaceutical ingredients that can be delivered transdermally
In October 2023, LUYE PHARMA AG, a pharmaceutical company, announced that its exclusive new drug, Rivastigmine Twice Weekly Transdermal Patch, has been approved by China's National Medical Products Administration (NMPA), for the symptomatic treatment of mild to moderate Alzheimer's disease (AD).
In March 2023, Teikoku Seiyaku Co., Ltd., a healthcare company, announced the launch of ALLYDONE Patches 27.5 mg / ALLYDONE Patches 55 mg in Japan, indicated for the suppression of progression of dementia symptoms in dementia due to Alzheimer’s disease
In June 2020, Vektor Pharma, a pharmaceutical company, announced the launch of the generic version of the transdermal Neupro patch (Rotigotine), used to ease the symptom of Parkinson’s disease.